(Q35034319)

5 August 2017

1 reference

title

Pharmacologic management of diabetic nephropathy (English)

1 reference

5 August 2017

Eva M Vivian

1

1 reference

PubMed ID

12501871

5 August 2017

Gail Breen Rubinstein

series ordinal

2

1 reference

5 August 2017

1 November 2002

1 reference

5 August 2017

Clinical Therapeutics

1 reference

5 August 2017

24

1 reference

5 August 2017

11

1 reference

5 August 2017

1741-56; discussion 1719

1 reference

Nephropathy in patients with type 2 diabetes mellitus

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Blood pressure and end-stage renal disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The link between hyperglycaemia and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Nephropathy in type 1 diabetes: the role of genetic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Smoking is associated with progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of different calcium antagonists on proteinuria associated with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Prospective randomised trial of early dietary protein restriction in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The effect of protein restriction on the progression of renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980076-5

7 January 2021

10.1016/S0149-2918(02)80076-5

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12501871